熱門資訊> 正文

4D分子治疗公司聘请克里斯蒂安·Humer担任首席财务官

2025-11-17 19:17

4D Molecular Therapeutics (FDMT) has appointed Kristian Humer as chief financial officer.
Humer is a seasoned finance executive and biotechnology leader with more than two decades of experience, including at Citi, Foghorn Therapeutics, and Viridian Therapeutics.
Source: Press Release

More on 4D Molecular Therapeutics

4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors
4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
4D Molecular Therapeutics stock rises after pricing $100M offering
Seeking Alpha’s Quant Rating on 4D Molecular Therapeutics
Historical earnings data for 4D Molecular Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。